3/5
08:04 am
eypt
Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.
High
Report
Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.
3/5
03:02 am
eypt
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]
High
Report
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]
3/4
03:24 pm
eypt
Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.
3/4
12:52 pm
eypt
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/4
10:57 am
eypt
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
07:25 am
eypt
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
Low
Report
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
3/4
07:00 am
eypt
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
Low
Report
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
3/2
07:13 am
eypt
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema [Yahoo! Finance]
Medium
Report
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema [Yahoo! Finance]
3/2
07:00 am
eypt
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
Medium
Report
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
2/25
07:18 am
eypt
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 [Yahoo! Finance]
Medium
Report
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 [Yahoo! Finance]
2/25
07:00 am
eypt
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
Medium
Report
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
2/24
07:00 am
eypt
EyePoint Announces Participation at Upcoming Investor Conferences
Low
Report
EyePoint Announces Participation at Upcoming Investor Conferences
2/18
07:00 am
eypt
EyePoint Appoints Michael Campbell as Chief Commercial Officer
Medium
Report
EyePoint Appoints Michael Campbell as Chief Commercial Officer
2/17
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2/5
07:00 am
eypt
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
1/16
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/7
07:13 am
eypt
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 [Yahoo! Finance]
Medium
Report
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 [Yahoo! Finance]
1/7
07:00 am
eypt
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
Medium
Report
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
12/23
02:27 pm
eypt
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains [Yahoo! Finance]
Low
Report
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains [Yahoo! Finance]
12/20
07:27 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Medium
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
12/17
07:56 am
eypt
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
07:00 am
eypt
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/16
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)